No Data
No Data
No Data
Addex Therapeutics Shareholders Greenlight Proposals
Addex Shareholders Approve All Resolutions at Annual General Meeting
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 1, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and
Earnings Call Summary | Addex Therapeutics(ADXN.US) Q1 2024 Earnings Conference
The following is a summary of the Addex Therapeutics Ltd (ADXN) Q1 2024 Earnings Call Transcript:Financial Performance:Addex Therapeutics reported a revenue of CHF0.2 million in Q1 2024, primarily fro
Addex Therapeutics Ltd (ADXN) Q1 2024 Earnings Call Transcript
Addex Therapeutics Ltd (ADXN) Q1 2024 Earnings Call Transcript
Addex Therapeutics GAAP EPS of -CHF 0.01, Revenue of CHF 0.24M
Addex Therapeutics Q1 Net Loss Widens, Income Drops
No Data